Current Edition


JW Pharma releases cancer treatment trial results

South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses Wnt signaling pathway, at the …

Continue Reading →

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →